Inc () CEO Doug Doerfler sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco.
Over the summer, the US FDA gave the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours.
Two weeks ago, the company began dosing its first patient.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
Meet MaxCyte, Primary Health Properties PLC, Scancell Holdings PLC and PCF Group Plc at our event,
London , 25 April 2019.
Register here »